Nectar Lifesciences Limited has successfully completed the acquisition of Avensis Exports Private Limited (AEPL) for ₹24.96 lakh, making it a wholly-owned subsidiary effective March 06, 2026. The pharmaceutical company had initially announced the acquisition plan during its board meeting on March 02, 2026, with an estimated consideration of 2.5 million rupees.

Acquisition Completion Details

The company informed stock exchanges through a regulatory filing that the acquisition was concluded on March 06, 2026, with payment made through normal banking channels. The final consideration amount was ₹24.96 lakh for acquiring 100% paid-up equity share capital of AEPL:

Strategic Business Expansion

The acquisition enables Nectar Lifesciences to diversify beyond its core pharmaceutical operations into the real estate sector. AEPL, incorporated on October 16, 2007, operates in the real estate business with a paid-up equity share capital of ₹8.00 lakh. Despite showing zero turnover for the last three years, AEPL's land exposures and collaborations with other real estate companies are expected to help establish Nectar Lifesciences' presence in the real estate arena.

Corporate Governance and Compliance

The transaction was structured as a non-related party deal, with none of Nectar Lifesciences' directors holding shareholding or directorship positions in AEPL. Company Secretary Sanjaymohan Singh Rawat signed the regulatory disclosure, confirming compliance with SEBI LODR Regulations and the Master Circular dated January 30, 2026.

Additional Corporate Changes

Alongside the acquisition, the board had also approved changing the company's Registrar and Share Transfer Agent from KFin Technologies Limited to Alankit Assignments Limited to reduce service costs and enhance operational efficiency:

Nectar lifesciences Limited has announced that its board of directors approved a significant inter-corporate loan facility during their meeting on March 02, 2026. The pharmaceutical company's board sanctioned an amount of up to INR 120 crores as a loan to its proposed wholly owned subsidiary, Avensis Exports Private Limited, following the completion of the acquisition process.

Board Meeting Details

The board meeting was conducted on Monday, March 02, 2026, commencing at 04:00 P.M. IST and concluding at 04:30 P.M. IST. The loan approval was part of broader decisions taken during this meeting, as referenced in the company's earlier disclosure dated March 02, 2026.

Regulatory Compliance and Disclosure

The company has committed to providing detailed disclosures regarding the loan agreement as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. These comprehensive disclosures will be submitted to the stock exchanges after the finalization of the definitive loan agreement with the proposed wholly owned subsidiary.

Nectar Lifesciences acknowledged an administrative oversight in the initial disclosure process, stating that the delay was inadvertent and unintentional. The company expressed regret for the omission and assured the exchanges of its commitment to furnishing all material information within prescribed time limits in the future.

Corporate Structure Development

The inter-corporate loan represents a strategic financial arrangement to support the operations of Avensis Exports Private Limited post-acquisition. The loan facility will be activated after the completion of the acquisition process, indicating the company's planned expansion of its corporate structure through the wholly owned subsidiary model.

The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders regarding this significant financial commitment. Company Secretary and Compliance Officer Sanjaymohan Singh Rawat signed the official communication to the stock exchanges on March 03, 2026.